© 2021 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
All News
Oyster Point Pharma unveils preclinical study results for Enriched Tear Film Gene Therapy to target ocular surface diseases
June 03, 2021
According to the company, preclinical study results from a 42-day proof-of-concept in vivo study demonstrated a single, intralacrimal gland injection of an adeno-associated virus containing the NGF gene produced statistically significant increase in NGF in tear film, as compared to placebo, as early as Day 7.
Increasing number of Americans prefer telehealth, poll finds
June 01, 2021
More Americans have used and continue to use teleheath for mental health care. according to a recent online poll by the American Psychiatric Association.
Upsher-Smith, Rafarm announce launch of moxifloxacin ophthalmic solution, USP 0.5%
May 27, 2021
Upsher-Smith Laboratories LLC and Rafarm SA have announced the U.S. commercial launch of moxifloxacin ophthalmic solution, USP 0.5% following a recent abbreviated new drug application (ANDA) approval by the FDA.
Outlook Therapeutics moving toward FDA approval of bevacizumab-vikg for treatment of wet AMD
May 27, 2021
The company is hoping to commercialize the first FDA-approved ophthalmic formulation of bevacizumab-vikg for retinal disease. It expects to receive BLA approval from the FDA by mid-2022.
National survey of frontline health care workers finds fear, unsafe working conditions
May 27, 2021
A new report by George Washington University offers a snapshot of health care workers during the COVID-19 pandemic and offers recommendations to prepare for the future.
Optical dispensary conversions
May 27, 2021
Practices can turn a moment of crisis into a win-win for all.
Nevakar announces formation of ophthalmic subsidiary, Vyluma
May 26, 2021
Vyluma Inc. will focus on the development and commercialization of therapies to treat ophthalmic diseases, including pediatric myopia.
NIH-funded grant to support research to determine which diabetic individuals can donate corneas for transplant
May 26, 2021
Backed by a five-year, $6.4 million grant from the National Eye Institute of the National Institutes of Health, investigators from Case Western Reserve University, University Hospitals and the Jaeb Center for Health Research hope to determine which diabetic patients can successfully donate their corneas for keratoplasty (and which should not).
Eyenovia announces positive topline results from VISION-1 Phase 3 clinical study of presbyopia therapeutic
May 25, 2021
The company plans to start a second Phase 3 registration study, VISION-2, as it continues on path toward a New Drug Application submission to the FDA.
Investigators receive grant to develop alternative to treat eye disease
May 24, 2021
A team of researchers at the University of Cincinnati's Department of Chemistry and Department of Ophthalmology, in collaboration with researchers at Cincinnati Children's Hospital Medical Center and the Ohio State University, have received a four-year, $1.6 million grant from the National Institutes of Health/National Eye Institute to develop a drug delivery system that is more efficient and longer lasting than conventional eye injections.